Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Liaoning Cancer Hospital & Institute
Zhejiang Cancer Hospital
Peking University
Xinjiang Medical University
Hebei Medical University Fourth Hospital
Fox Chase Cancer Center
Fondazione Italiana Linfomi - ETS
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie